Cline Scientific, NecstGen Team Up on Damaged Cartilage Therapy

Cline Scientific and NecstGen have signed a Letter of Intent to develop and manufacture clinical batches of Cline’s cell therapy for cartilage repair, StemCART.

“This LOI [letter of intent] is an important first step in Cline’s preparation for the clinical phases of StemCART and a principal component of the manufacturing strategy,” Cline Scientific CEO Hanne Evenbratt said. “We are very excited to move forward with the team at NecstGen and anticipate a prosperous collaboration.”
 
Through the partnership, NecstGen will support the further development and manufacture of Cline’s cell therapy for damaged cartilage, StemCART, an advanced therapy medicinal product (ATMP) that aims to revolutionize cartilage damage treatment. The Swedish therapy developer envisions to out-license StemCART to a commercial partner following successful in-human trial results.  
 
“We are happy to support Cline Scientific throughout this critical phase in the development of its StemCART therapy. This potential joint action is very much a demonstration of our mission to support organizations developing therapies for patients,” NecstGen CEO Paul Bilars stated.
 
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Its patented surface nanotechnology provides solutions to critical challenges for cell-based products and processes in life science. Cline is driving two projects through to a clinical-stage—StemCART, a stem cell therapy for joint repair, and CellRACE, a cancer diagnostic to predict metastasis.
 
NecstGen is a centre of excellence for cell and gene therapy, located in a large 4,000-square-meter purpose-built GMP facility on the biggest bio-cluster in the Netherlands, Leiden Bio Science Park. NecstGen provides critical contract development, manufacturing and rental services to all therapy developers who aim to deliver the next generation of treatments to patients.